Table 1. At five years after the start of the study 91.4% of the cases were being administered Pravastatin (ref 18).
| Year 1 | Year 3 | Year 5 | Year 7 | Year 9 | |
|---|---|---|---|---|---|
| Diet group | |||||
| Patients* | 3814 | 3627 | 2604 | 455 | 237 |
| Actual visits† | 3705 | 3354 | 2291 | 447 | 222 |
| No lipid-lowering drug | 3070 (83%) | 2398 (71%) | 1518 (66%) | 259 (58%) | 115 (52%) |
| Pravastatin | 311 (8%) | 586 (17%) | 520 (23%) | 147 (33%) | 86 (39%) |
| Other statin | 20 (1%) | 49 (1%) | 43 (2%) | 6 (1%) | 5 (2%) |
| Other lipid-lowering drug | 304 (8%) | 321 (10%) | 210 (9%) | 35 (8%) | 16 (7%) |
| Diet plus pravastatin group | |||||
| Patients* | 3678 | 3473 | 2545 | 467 | 259 |
| Actual visits† | 3574 | 3251 | 2252 | 451 | 242 |
| 20 mg pravastatin | 230 (6%) | 461 (14%) | 374 (17%) | 114 (25%) | 54 (22%) |
| 15 mg pravastatin | 4 (0.1%) | 12 (0.4%) | 10 (0.4%) | 3 (0.7%) | 3 (1%) |
| 10 mg pravastatin | 2896 (81%) | 2322 (71%) | 1522 (68%) | 285 (63%) | 152 (63%) |
| 5 mg pravastatin | 265 (7%) | 207 (6%) | 130 (6%) | 15 (3%) | 7 (3%) |
| Other statin | 6 (0.2%) | 7 (0.2%) | 17 (0.8%) | 3 (0.7%) | 5 (2%) |
| Other lipid-lowering drug | 14 (0.4%) | 29 (1%) | 22 (1%) | 8 (2%) | 5 (2%) |
| No lipid-lowering drug | 159 (4%) | 213 (7%) | 177 (8%) | 23 (5%) | 16 (7%) |
*
Number at risk of total mortality.
†
Number of patients who visited the hospital. Any patients who fitted in several categories were assigned to upper category in the table.